|Cornell University / Sloan-Kettering Institute, Ph.D.|
|Genetics / Cell Biology|
|Cornell University Medical College, M.D.|
|Dartmouth College, B.S.|
Hoyoung Huh is the chairman of Geron Corporation, where he has also held executive chairman and director positions, and is on the board of directors for Addex Pharmaceuticals and BayBio. Dr. Huh has been involved in the formation, management and financing of more than 20 successful entities across the United States, Europe and Asia.
He was previously the president, CEO and chairman of BiPar Sciences, Inc., which was acquired by Sanofi-aventis for $500 million in 2009.
Prior to that, he served as the chairman of Epizyme, Inc., chief operating officer and board member of Nektar Therapeutics and board member of Facet Biotech, which was acquired by Abbott Laboratories for $722 million in 2010.
Dr. Huh was formerly a partner at McKinsey & Company in the healthcare and technology practices.
Dr. Huh holds a B.S. in biochemistry from Dartmouth College, an M.D. from Cornell University Medical College, and a Ph.D. in genetics/cell biology from Cornell University/Sloan-Kettering Institute.